Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB - Get Free Report) Director Aron R. English bought 10,101,010 shares of the business's stock in a transaction that occurred on Monday, December 23rd. The shares were acquired at an average price of $0.99 per share, with a total value of $9,999,999.90. Following the transaction, the director now directly owns 15,467,300 shares of the company's stock, valued at $15,312,627. This represents a 188.23 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Anebulo Pharmaceuticals Price Performance
Shares of ANEB stock opened at $1.62 on Friday. The company's fifty day simple moving average is $1.57 and its two-hundred day simple moving average is $1.93. Anebulo Pharmaceuticals, Inc. has a 52 week low of $0.80 and a 52 week high of $3.30. The stock has a market cap of $42.01 million, a P/E ratio of -5.40 and a beta of -1.09.
Anebulo Pharmaceuticals (NASDAQ:ANEB - Get Free Report) last posted its earnings results on Wednesday, September 25th. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.08. On average, analysts anticipate that Anebulo Pharmaceuticals, Inc. will post -0.52 EPS for the current fiscal year.
Analysts Set New Price Targets
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
From Crypto Swap Profits | Ad
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days.
It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year.
This is where fortunes are made – often LITERALLY overnight.
>> Register for the Workshop Now
Separately, Benchmark reaffirmed a "speculative buy" rating and set a $8.00 price objective on shares of Anebulo Pharmaceuticals in a report on Tuesday, November 19th.
Read Our Latest Stock Analysis on Anebulo Pharmaceuticals
About Anebulo Pharmaceuticals
(
Get Free Report)
Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
